Significant clusters: Coronal PET images showing brain regions with significant (p < 0.001 and K > 50) metabolic inhibition (A-G) and activation (H-I) in rats following cocaine sel... حسب Christopher Rowan (21499924)

Videofluoroscopic swallowing study parameters. حسب Rie Asayama (693361)

الموضوعات:

Interventions for Psychological Stress in Pregnant African American Women: A Scoping Review حسب Taleah A. Frazier (22423294)

الموضوعات:

S1 File - Utilization of psychotropic drugs in Serbia from 2006 to 2021: Patterns before and during the COVID-19 pandemic حسب Jelena Filimonovic (22305307)

الموضوعات:

Anion-Assisted Glycosylation of Galactose: A Computational Study حسب Kerli Tali (22769704)

الموضوعات:

Characteristics of the included studies. حسب Xin Liu (43569)

الموضوعات:

Summary of results. حسب Xin Liu (43569)

الموضوعات:

Bias risk assessments for each RCT study. حسب Xin Liu (43569)

الموضوعات:

The flow chart of studies selecting. حسب Xin Liu (43569)

الموضوعات:

Funnel plots for intraoperative blood loss. حسب Xin Liu (43569)

الموضوعات:

Bias risk assessments for each RCS study. حسب Xin Liu (43569)

الموضوعات:

Table2_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.DOCX حسب Sofia Schaeffer (20379954)

"…HC 45.4 min vs. 21.3 min, p = 0.0004), and decreased sleep efficiency (MASLD vs. HC 86.5% vs. 92.8%, p = 0.0008) compared with HC despite comparable sleep duration. …"

Table1_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.DOCX حسب Sofia Schaeffer (20379954)

"…HC 45.4 min vs. 21.3 min, p = 0.0004), and decreased sleep efficiency (MASLD vs. HC 86.5% vs. 92.8%, p = 0.0008) compared with HC despite comparable sleep duration. …"

Shares of antibiotic substances on total prescription in UTI treatment (N39.0, N30.0) by sex and age group in 2019 (female: n = 238.670 prescriptions; male: n = 40.641 prescription... حسب Thomas Hanslmeier (19949694)

الموضوعات: "…fluoroquinolone shares decreased…"

Shares of antibiotic substances on total prescription by quarter from 2013 to 2019 for female and male patients with UTI (N39.0, N30.0)(female: n = 1.681.255 prescriptions; male: n... حسب Thomas Hanslmeier (19949694)

الموضوعات: "…fluoroquinolone shares decreased…"

Shares of specialist groups prescribing 1^st, 2^nd, and 3^rd antibiotic prescriptions in UTI treatment of females (N39.0, N30.0) in 2018 and 2019. حسب Thomas Hanslmeier (19949694)

الموضوعات: "…fluoroquinolone shares decreased…"

Number of antibiotic prescriptions in female and male patients with UTI (N30.0 and/or N39.0). حسب Thomas Hanslmeier (19949694)

الموضوعات: "…fluoroquinolone shares decreased…"

Shares of antibiotic substances on total prescription in female patients with UTI (N39.0, N30.0) by physician specialties (GPs: n = 1.299.641 prescriptions; gynecologists n = 141.8... حسب Thomas Hanslmeier (19949694)

الموضوعات: "…fluoroquinolone shares decreased…"

Comparison of 1^st, 2^nd, and 3^rd antibiotic prescription. حسب Thomas Hanslmeier (19949694)

الموضوعات: "…fluoroquinolone shares decreased…"

UTI diagnoses by sex and physician specialty (2013–2019). حسب Thomas Hanslmeier (19949694)

الموضوعات: "…fluoroquinolone shares decreased…"